NEW YORK (GenomeWeb News) – UK-based Asterand today said that it will acquire BioSeek, a developer of cell-based assay systems, in a deal worth up to $14 million.

Asterand, which provides tissue-based services for drug discovery, said that the acquisition will provide it with highly complementary technologies, specifically BioSeek's BioMap platform and human cell-based assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.